Literature DB >> 25736542

Sensitization to Api m 1, Api m 2, and Api m 4: association with safety of bee venom immunotherapy.

Berta Ruiz1, Pilar Serrano2, Miriam Verdú3, Carmen Moreno2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25736542     DOI： 10.1016/j.anai.2015.01.010

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN： 1081-1206            Impact factor:   6.347


× No keyword cloud information.
  4 in total

1.  Expression of eosinophils, RANTES and IL-25 in the first phase of Hymenoptera venom immunotherapy.

Authors:  Krzysztof Pałgan; Magdalena Żbikowska-Götz; Zbigniew Bartuzi
Journal:  Postepy Dermatol Alergol       Date:  2019-04-01       Impact factor: 1.837

Review 2.  Component resolved diagnostics for hymenoptera venom allergy.

Authors:  Thilo Jakob; Ulrich Müller; Arthur Helbling; Edzard Spillner
Journal:  Curr Opin Allergy Clin Immunol       Date:  2017-10

3.  Anaphylactic reactions in the build-up phase of rush immunotherapy for bee venom allergy in pediatric patients: a single-center experience.

Authors:  Antonia Glaeser; Christoph Müller; Sebastian Bode
Journal:  Clin Mol Allergy       Date:  2022-04-29

Review 4.  Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes.

Authors:  Simon Blank; Johannes Grosch; Markus Ollert; Maria Beatrice Bilò
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.